Compare Nebius Group NV (NBIS) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nebius Group NV vs Sana Biotechnology Inc — how do they compare? Nebius Group NV trades at $220.95 (market cap $59.73B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Nebius Group NV is far larger — about 71.4× Sana Biotechnology Inc's market cap, and Nebius Group NV is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nebius Group NV for 24 Days and Sana Biotechnology Inc for 23 Days on average.
| NBIS | SANA | |
|---|---|---|
Market Cap | $59.73B | $836.71M |
Volume | 21,563,700 | 4,507,444 |
Sector | Technology | Health |
52-Week High | $286.69 | $5.92 |
52-Week Low | $73.87 | $2.68 |
Typical Hold Time | 24 Days | 23 Days |
Enterprise Value | $61.86B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NBIS trades at $220.95, down 6.8% on the day, with a bearish technical signal and high valuation ratios (P/E of 845.04). The company reported a net income of $82.50M in 2025, but recent quarterly EPS showed mixed results against expectations. Analyst consensus remains strongly bullish with a price target of $288.67, supported by significant revenue growth projections and strategic AI infrastructure deals.
The outlook for NBIS is clouded by high execution risks amid aggressive expansion, negative cash flow from investing, and insider selling. While analyst optimism and AI demand offer upside potential, investors face volatility from valuation concerns and competitive pressures in the cloud infrastructure sector.
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
